ERGOLOID MESYLATES
Clinical safety rating: safe
Animal studies have demonstrated safety
Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.
| Metabolism | Hepatic metabolism via CYP3A4 primarily; extensive first-pass effect. |
| Excretion | Primarily fecal (biliary) as metabolites and unchanged drug; renal elimination accounts for less than 10% of the dose. |
| Half-life | 2-4 hours for parent drug; clinical significance: drug accumulation unlikely with normal dosing intervals. |
| Protein binding | Approximately 90% bound to albumin. |
| Volume of Distribution | 1.5-2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: less than 10% due to extensive first-pass metabolism. |
| Onset of Action | Oral: Effects on mental status may be observed within 3-5 weeks of continuous therapy; not immediate. |
| Duration of Action | Effects are sustained over time with chronic dosing; no acute duration defined as continuous therapy is required for clinical benefit. |
Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.
| Dosage form | TABLET |
| Renal impairment | Not studied; no specific recommendations. Caution advised in severe renal impairment (GFR <30 mL/min). |
| Liver impairment | Contraindicated in Child-Pugh class C (severe hepatic impairment). Use with caution in Child-Pugh class B; reduce dose by 50%. |
| Pediatric use | Not established; safety and efficacy not determined in pediatric patients. |
| Geriatric use | Initiate at 1 mg twice daily; titrate slowly. Monitor for orthostatic hypotension and cognitive effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Not for use in the treatment of psychosis or acute mental disorders.
| Breastfeeding | Excreted into breast milk; M/P ratio unknown. May suppress prolactin and reduce milk production. Potential for ergotism in neonates (vomiting, diarrhea, convulsions). Contraindicated during breastfeeding. |
| Teratogenic Risk | Ergoloid mesylates are ergot derivatives with uterotonic properties. First trimester: Avoid due to potential teratogenicity (limb defects, CNS malformations) based on animal data. Second/Third trimester: Contraindicated due to oxytocic effects causing uterine hypertonicity, placental hypoperfusion, and fetal distress. Use only if benefit outweighs risk for life-threatening conditions. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Nausea |
| Serious Effects |
Hypersensitivity to ergot alkaloids; severe hypotension; acute or chronic psychosis; concurrent use with potent CYP3A4 inhibitors (e.g., macrolide antibiotics, azole antifungals).
| Precautions | Use with caution in patients with hypotension, bradycardia, or history of psychosis; may cause orthostatic hypotension; monitor for signs of ergotism. |
Loading safety data…
| Fetal Monitoring | Monitor uterine activity (tocography) if used during pregnancy; fetal heart rate monitoring for signs of distress. In postpartum, monitor for excessive bleeding or vasospasm. Assess maternal blood pressure and signs of ergotism (numbness, tingling, chest pain). |
| Fertility Effects | Ergoloid mesylates may inhibit prolactin secretion, potentially impairing ovulation and fertility. Use for hyperprolactinemia-induced infertility may restore ovulation but risk of pregnancy requires contraception during therapy. |